Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 58.38 |
---|---|
High | 60.96 |
Low | 58.38 |
Bid | 62.00 |
Offer | 63.61 |
Previous close | 58.97 |
Average volume | 14.30 |
---|---|
Shares outstanding | 61.46m |
Free float | 57.68m |
P/E (TTM) | -- |
Market cap | 4.14bn USD |
EPS (TTM) | -4.31 USD |
Data delayed at least 15 minutes, as of Nov 08 2024 18:30 GMT.
More ▼
Announcements
- Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences
- Rhythm Pharmaceuticals Reports Third Quarter 2024 Financial Results and Business Update
- Rhythm Pharmaceuticals Announces Five New Data Presentations at ObesityWeek® 2024
- Rhythm Pharmaceuticals and Axovia Therapeutics Announce Joint Research Collaboration in Bardet-Biedl Syndrome
- Rhythm Pharmaceuticals to Report Third Quarter 2024 Financial Results on Tuesday, November 5, 2024
- Rhythm Pharmaceuticals Announces New Employment Inducement Grants
- Rhythm Pharmaceuticals Announces FDA Acceptance for Priority Review of Supplemental New Drug Application for IMCIVREE® (setmelanotide) in Patients as Young as 2 years old
- Rhythm Pharmaceuticals to Present at Wells Fargo Healthcare Conference in September
- Rhythm Pharmaceuticals Reports Second Quarter 2024 Financial Results and Business Update
- Rhythm Pharmaceuticals Announces European Commission Expands ▼IMCIVREE® (setmelanotide) Marketing Authorization to include Children as Young as 2 Years Old
More ▼